A placebo-controlled trial shows tezepelumab significantly reduces oral corticosteroid dependence in severe asthma, with patients achieving nearly three times the odds of reduction versus placebo. A separate case report documents dramatic functional recovery in an elderly patient who switched from mepolizumab to tezepelumab after inadequate response.
CARsgen Therapeutics has signed a RMB370 million agreement to build a CAR T-cell manufacturing base in Shanghai, supporting commercialization of its marketed and late-stage products. Meanwhile, investment firm HarbourVest disclosed a $21 million position in CAR-T developer Generate Biomedicines, which holds $516.6 million in cash after its IPO.
Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.
The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07757841 |
Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis |
NOT_YET_RECRUITING | NA |
| NCT07735494 |
Physical Activity Promotion and Clinical Remission in Severe Asthma |
RECRUITING | NA |
| NCT07721376 |
Multi-omics in Severe Asthma From Olive Pollen Allergy |
ACTIVE_NOT_RECRUITING | |
| NCT07713498 |
Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes |
ENROLLING_BY_INVITATION | |
| NCT07655037 |
Execise Intervention in Adult Severe Asthma |
RECRUITING | NA |
| NCT07654842 |
Fasenra: An Asthma Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT07532265 |
A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma |
RECRUITING | PHASE2 |
| NCT07530770 |
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis |
RECRUITING | |
| NCT07393984 |
Digital Self-Monitoring in Severe Asthma |
COMPLETED | NA |
| NCT07363642 |
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab |
RECRUITING | PHASE3 |
